This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A recently released white paper calls for updating FDA regulations around the development of cell therapies. The authors suggest changing the investigational new drug pathway exploratory trials, including easing manufacturing requirements for early studies and allowing for greater flexibility to revise protocols as studies progress.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
Call Made to Speed Cell-Therapy Development
Jump to section
Advertisement